Rinofast aerosol nasal congestion: what it helps with according to the clinical study using the SNOT-22 test
Nasal congestion is not just a “blocked nose”: it often means mucus stagnation, thick secretions that are hard to clear, post-nasal drip–related cough, and more fragmented sleep.
To measure the real-life impact of these symptoms (not only “how well you breathe,” but how you feel in everyday life), guidelines and clinical literature use validated tools such as SNOT-22: Sino-Nasal Outcome Test; it is a validated questionnaire that assesses how nasal and rhinosinusitis symptoms (e.g., blocked nose, runny nose, cough, sleep disturbances) affect quality of life through a score.
In this context, Rinofast aerosol fits as a 3% hypertonic solution designed to support mucus thinning and removal and help restore mucociliary clearance, with a direct impact on breathing comfort.
The data reported refer to an observational clinical study conducted by Gruppo FarmaImpresa in May 2025. The research assessed the effectiveness of Rinofast aerosol as support in the management of nasal congestion and rhinosinusitis-related symptoms associated with reduced mucociliary clearance.
What Rinofast aerosol is and why it helps when mucus “gets stuck”
Rinofast aerosol is a ready-to-use hypertonic saline solution (NaCl 3%). Thanks to its osmotic action, it supports the restoration of normal mucociliary clearance and helps to thin, transport, and remove mucus—supporting decongestion and respiratory function.
Rinofast aerosol clinical study: methodology and results
The SNOT-22 graph shows a clear improvement in symptoms after treatment with Rinofast aerosol: the total score, measured at baseline (T0) and re-assessed at follow-up (T1) after about 1 week ± 3 days, drops markedly in the sample of 20 children.
75% of patients (15 out of 20) achieved a reduction greater than 50% in the SNOT-22 score, suggesting a noticeable benefit on typical issues such as blocked nose, secretions, and sleep impact.
Key results: reduction in the SNOT-22 score
The key finding is a marked reduction in the total score:
Even easier to understand (and very useful from a marketing perspective): 15 out of 20 patients (75%) achieved a >50% reduction in the score.
Who Rinofast aerosol is indicated for
Rinofast aerosol is suitable for children as well and can be used as support in cases of:
SNOT-22 total (median [IQR]): 76.00 at T0 → 32.00 at T1
Median difference: 42.00 points
Statistical significance: p < 0.001
- Nasal congestion and daily nasal discharge, especially when mucus tends to stagnate
- Helps thin and remove mucus
- Useful for daily nasal hygiene
- Supports mucociliary clearance
How to use it?
Rinofast aerosol comes in practical, hygienic resealable vials designed for flexible use: once opened, they can be closed again and reused within 12 hours.
It also offers a double administration route to adapt to different needs: it can be used for aerosol therapy/inhalation (1 vial, 1–2 times per day) or for direct nasal irrigation (half a vial per nostril, 2–3 times per day), supporting congestion management and mucus removal.
Looking for a solution ready for B2B distribution or private label?
We are certified manufacturers of medical devices, dietary supplements, and cosmetics. Rinofast aerosol (FT.CE.114) is ready for market launch or available in private label format, with full regulatory and clinical support.
